title: Thalidomide for the treatment of leptomeningeal multiple myeloma.
authors.forename: Hattori
authors.initials: H
authors.lastname: Yutaka
authors.forename: Yabe
authors.initials: Y
authors.lastname: Mariko
authors.forename: Okamoto
authors.initials: O
authors.lastname: Shinichiro
authors.forename: Morita
authors.initials: M
authors.lastname: Kunihiko
authors.forename: Tanigawara
authors.initials: T
authors.lastname: Yusuke
authors.forename: Ikeda
authors.initials: I
authors.lastname: Yasuo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008558:Melphalan / Q000008:administration & dosage; D008577:Meningeal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage*; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D020533:Angiogenesis Inhibitors; D007074:Immunoglobulin G; D009607:Nitrosourea Compounds; D013792:Thalidomide; D005047:Etoposide; D004317:Doxorubicin; D011239:Prednisolone; D008558:Melphalan; D014751:Vindesine; D011241:Prednisone